Related Experiment Video
Updated: Aug 9, 2026
07:14
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
Ropinirole: current status of the studies
1Dept. of Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191 Wiesbaden, Germany. jost.neuro@dkd-wiesbaden.de
Journal of Neurology
|January 29, 2005
Summary
Ropinirole effectively treats Parkinson's disease and restless legs syndrome. It improves motor symptoms, daily living, and mood while reducing L-dopa complications.
Area of Science:
- Neurology
- Pharmacology
Background:
- Idiopathic Parkinson's disease (IPD) presents significant motor and non-motor symptoms.
- Levodopa (L-dopa) is a common treatment but associated with long-term complications.
- Dopamine agonists offer an alternative therapeutic approach for IPD.
Purpose of the Study:
- To evaluate the efficacy of ropinirole in treating idiopathic Parkinson's disease.
- To assess ropinirole's impact on daily living activities and mood.
- To explore ropinirole's role in managing L-dopa complications and its potential neuroprotective effects.
Main Methods:
- Clinical studies assessing ropinirole as monotherapy and combination therapy for IPD.
- Evaluation of motor symptoms (bradykinesia, rigor, tremor).
- Assessment of non-motor symptoms, daily living abilities, and mood.
Main Results:
- Ropinirole demonstrated efficacy in improving bradykinesia, rigor, and tremor.
- Significant amelioration of daily living abilities and depressive mood was observed.
- Reduction in both existing and long-term complications associated with L-dopa therapy.
Conclusions:
- Ropinirole is an effective non-ergoline dopamine agonist for Parkinson's disease.
- It offers benefits beyond motor symptom control, including mood and functional improvement.
- Ropinirole may mitigate L-dopa-related issues and warrants further investigation for neuroprotective properties.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...